Retatrutide Side Effects: What the Phase 3 Trials Actually Found
Quick answer: The most common retatrutide side effects are gastrointestinal — nausea affected 42.4% of participants at the 12 mg dose in TRIUMPH-1, alongside diarrhoea, constipation, and vomiting. The signal specific to retatrutide is dysesthesia, an altered skin sensation reported in 12.5% to 20.9% of participants at 12 mg depending on the trial. Heart rate rose 5–10 bpm on average. Serious adverse events occurred at the same rate as placebo in Phase 2. Retatrutide is investigational and has no approved safety labelling.
Gastrointestinal Side Effects: The Dominant Pattern
Retatrutide shares the gastrointestinal profile of the whole incretin class. These were the most frequently reported events in every trial, and they are strongly dose-dependent.
From TRIUMPH-1, the pivotal obesity trial of 2,339 adults over 80 weeks:
| Side effect | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhoea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
Percentage of participants reporting each event over 80 weeks (n=2,339)
Source: Eli Lilly TRIUMPH-1, full data presented at the ADA 86th Scientific Sessions, June 2026. Retatrutide is investigational; these are trial observations, not prescribing information.
Two things stand out. Placebo rates are not zero — roughly one in seven placebo participants reported nausea, which is a reminder that not every symptom during treatment is caused by the drug. And diarrhoea does not rise cleanly with dose; the 9 mg rate slightly exceeds 12 mg, suggesting the dose-response relationship is not uniform across every symptom.
In trials, these events clustered during the titration period rather than persisting throughout. Both TRIUMPH-1 and TRIUMPH-4 used a stepwise escalation from 2 mg up to the target dose across roughly 12 to 16 weeks, and gastrointestinal events were concentrated in the weeks following each increase.
Dysesthesia: The Side Effect Specific to Retatrutide
Dysesthesia is an abnormal sense of touch. People describe it as tingling, burning, prickling, or skin that feels unusually sensitive to clothing, water, or pressure. It is not pain from injury and it is not an allergic reaction — ordinary sensations simply register as strange or uncomfortable.
The mechanism is unconfirmed, but the leading explanation points at the glucagon receptor — the same third target that drives the drug’s energy expenditure advantage. See how retatrutide works and why the third receptor matters.
This is the finding that separates retatrutide from semaglutide and tirzepatide, and it did not appear in the Phase 2 trial. It emerged only when Phase 3 tested higher doses in larger populations over longer periods.
It is also sharply dose-dependent, which is the most practically important thing about it:
| Trial | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| TRIUMPH-4 (n=445, knee osteoarthritis) | 8.8% | 20.9% | 0.7% |
| TRIUMPH-1 (n=2,339, general obesity) | — | 12.5% | — |
Same dose, different populations, nearly double the rate
Sources: Eli Lilly TRIUMPH-4 topline, December 2025; TRIUMPH-1 full data, ADA 86th Scientific Sessions, June 2026. TRIUMPH-1 did not report a separate 9 mg dysesthesia rate.
Why the two trials disagree
Most coverage of retatrutide side effects quotes either 20.9% or 12.5% without addressing the gap. Both figures are from Phase 3, both at 12 mg, and they differ by a factor of nearly two.
The likeliest explanation is population. TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis — an older cohort with higher baseline BMI and existing joint pathology, where altered sensation may be both more likely and more likely to be reported. TRIUMPH-1 enrolled a general obesity population and is more than five times larger, which makes its 12.5% the more representative figure for most people.
Trial size matters here too. A 445-participant trial produces a wider confidence interval than a 2,339-participant one. When two estimates conflict, the larger and more general study is usually the better guide.
In both trials, dysesthesia was described as mild to moderate, rarely led to discontinuation, and in many cases resolved while participants remained on treatment. It remains the signal most likely to draw scrutiny during review — why this signal matters for the FDA review.
Heart Rate: The Glucagon-Related Signal
Retatrutide produced a dose-dependent heart rate increase of roughly 5 to 10 beats per minute across trials. The pattern was consistent: rates rose, peaked around week 24, then declined with continued treatment.
Modest heart rate elevation is a known class effect of GLP-1 receptor agonists, so this is not unique to retatrutide. But the magnitude appears somewhat larger, which is plausibly connected to glucagon receptor activation — the same mechanism responsible for the increased energy expenditure that drives retatrutide’s weight loss advantage.
No major adverse cardiovascular events were attributed to the drug in trials reported so far. TRIUMPH-3, the dedicated cardiovascular outcomes trial in adults with established cardiovascular disease, has not yet reported. Until it does, the long-term cardiovascular picture is incomplete.
How Many People Stopped Because of Side Effects
Discontinuation due to adverse events is the practical measure of tolerability — it captures whether side effects were bad enough that people quit.
| Trial and dose | Discontinued due to adverse events |
|---|---|
| TRIUMPH-1, 4 mg | 4.1% |
| TRIUMPH-1, overall | ~11% |
| TRIUMPH-1, placebo | 4.9% |
| TRIUMPH-4, 9 mg | 12.2% |
| TRIUMPH-4, 12 mg | 18.2% |
| TRIUMPH-4, placebo | 4.0% |
| Phase 2, 12 mg | 8.3% |
The 4 mg result in TRIUMPH-1 is the most interesting number in the whole safety dataset. At 4.1%, discontinuation was marginally below the 4.9% placebo rate — while still producing 19.0% weight loss. That suggests the escalation schedule and the top doses, rather than the compound itself, account for most dropouts.
That pattern points back to the titration protocol rather than the compound — how the escalation schedule drives these rates covers the schedule step by step.
TRIUMPH-4’s much higher rates reinforce the population point: the osteoarthritis cohort tolerated the drug considerably worse than the general obesity population, and higher baseline BMI was associated with greater likelihood of stopping.
Serious Adverse Events and What Is Still Being Monitored
In the Phase 2 trial, serious adverse events occurred in 4% of retatrutide participants and 4% of placebo participants — no separation between groups. TRIUMPH-1 additionally recorded upper respiratory and urinary tract infections, with most urinary and neurological events resolving during active treatment.
Pancreatitis and gallbladder complications are tracked across this drug class and were not significantly elevated in retatrutide trials, though rapid weight loss is itself an independent risk factor for gallstones. GLP-1 receptor agonists as a class carry warnings regarding thyroid C-cell tumours based on rodent studies; what retatrutide’s eventual labelling says on this will be determined during FDA review, not before it.
How Retatrutide Compares on Tolerability
| Retatrutide | Tirzepatide | Semaglutide | |
|---|---|---|---|
| GI side effects | Yes, dose-dependent | Yes, dose-dependent | Yes, dose-dependent |
| Dysesthesia | 12.5–20.9% at 12 mg | Not characteristic | Not characteristic |
| Heart rate increase | 5–10 bpm | Class effect, smaller | Class effect, smaller |
| Discontinuation (AE) | ~4–18% by dose and trial | ~5–7% | ~7% |
| Real-world safety data | None — trials only | Years, millions of patients | Years, millions of patients |
| Cardiovascular outcomes trial | Not yet reported | Completed | Completed |
The bottom two rows carry more weight than the rest. Retatrutide’s side effect profile looks broadly comparable to its class on gastrointestinal measures, with dysesthesia as the genuine addition. What it lacks entirely is post-approval evidence — the rare events that only surface once a drug is used by large populations outside controlled trials. For efficacy alongside tolerability, see the full comparison on efficacy and tolerability.
What We Still Do Not Know
These figures describe what treatment cost participants. The efficacy results these tolerability figures accompany are the other half of the picture.
- Long-term cardiovascular outcomes — TRIUMPH-3 has not reported
- What causes the dysesthesia — the leading hypothesis involves glucagon receptor activity or rapid metabolic change affecting peripheral nerves, but this has not been established
- Rare adverse events — trials of a few thousand people cannot detect events occurring in one in ten thousand
- Effects beyond 104 weeks — the longest reported follow-up
- What happens after stopping — weight regain patterns after discontinuation have not been characterised for retatrutide
All safety data on this page comes from clinical trials in which participants were screened, dosed under protocol, and medically monitored. None of it constitutes prescribing information, because no approved prescribing information exists.
For the trial data, dosing schedules, and regulatory tracking behind all of this, browse the complete retatrutide research library.
Frequently Asked Questions
What are the most common retatrutide side effects?
Gastrointestinal events dominate: nausea (42.4% at 12 mg), diarrhoea (32.0%), constipation (26.1%), and vomiting (25.3%) in TRIUMPH-1. All were dose-dependent and concentrated during dose escalation.
What is dysesthesia and how common is it?
An abnormal sense of touch — tingling, burning, or unusual skin sensitivity. It occurred in 12.5% of participants at 12 mg in TRIUMPH-1 and 20.9% in TRIUMPH-4. It was generally mild and often resolved during continued treatment.
Does retatrutide affect heart rate?
Yes, by roughly 5–10 bpm on average, peaking around week 24 before declining. Modest heart rate increase is a known effect across this drug class.
Are retatrutide side effects worse than tirzepatide’s?
Gastrointestinal effects are broadly comparable. Retatrutide adds dysesthesia, which tirzepatide does not produce, and shows a somewhat larger heart rate effect. Tirzepatide has years of real-world safety data that retatrutide entirely lacks.
Do retatrutide side effects go away?
In trials, gastrointestinal events were concentrated during dose escalation and diminished at stable doses. Heart rate elevation peaked at week 24 and then declined. Dysesthesia frequently resolved while participants stayed on treatment.
Is retatrutide safe?
Its safety profile is still being established and no regulator has reviewed it. Serious adverse events matched placebo in Phase 2, but the cardiovascular outcomes trial has not reported and there is no post-approval data. Safety questions about any treatment belong with a licensed clinician.
Which dose has the fewest side effects?
In TRIUMPH-1, the 4 mg arm produced the lowest discontinuation rate — 4.1%, marginally below placebo — while still achieving 19.0% weight loss. Dysesthesia at 9 mg was 8.8% versus 20.9% at 12 mg in TRIUMPH-4. These are trial observations, not dosing guidance; no approved dosing exists.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389:514–526.
- Eli Lilly. TRIUMPH-1 topline results, May 21 2026; full data presented ADA 86th Scientific Sessions, June 6 2026.
- Eli Lilly. TRIUMPH-4 topline results, December 2025.
- Bajaj HS, et al. “Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1).” The Lancet. 2026.
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066), TRIUMPH-3, TRIUMPH-4.